Toxicology News and Research

Latest Toxicology News and Research

JANA Partners sends detailed critique of Charles River's revised investor presentation on WuXi acquisition

JANA Partners LLC today sent Charles River Laboratories International, Inc. a detailed critique of Charles River's revised investor presentation released earlier this week, in which Charles River once again seeks to persuade shareholders of the merits of its proposed acquisition of WuXi PharmaTech (Cayman) Inc..

17 Jul 2010

Long-term exposure of arsenic may increase risk for lung cancer

To determine how arsenic increases the risk of lung cancer and to identify potential treatments, a Michigan State University researcher will use $1.7 million in federal funding during the next five years to examine why certain genes disrupt cells, leading to the disease.

15 Jul 2010

Variations in quality of illegal Class B drug mephedrone could risk safety of users

Pharmaceutical scientists have discovered that the recently reclassified drug mephedrone varies in quality so much that users could be at risk of overdosing. Six samples were tested in the University of Sunderland's labs by Dr John Lough and his team, and although impurities levels were low, three samples revealed various particle size and crystalline form, which means that the drug is more likely to vary in its affect and safety on the user.

15 Jul 2010

Maven Semantic announces updates to database of Toxicology researchers

Maven Semantic announces updates to their Toxicology database.

14 Jul 2010

Research provides understanding of EGME's effects on metabolism

Metabolon, Inc., the leader in global metabolism, biomarker discovery and analysis, announces the publication of "Ethylene Glycol Monomethyl Ether-Induced Toxicity is Mediated through the Inhibition of Flavoprotein Dehydrogenase Enzyme Family", in the journal Toxicological Sciences on July 8, 2010. The paper was co-authored by Dr. Makoto Takei and colleagues at Daiichi-Sankyo in collaboration with Metabolon scientists.

14 Jul 2010

Affygility Solutions releases new version of Affytrac EH&S software with multi-corrective action functionality

Affygility Solutions, LLC, a global leader in providing environmental, health and safety solutions to the life sciences industry, announced today the launch of its newest version of its environmental, health, and safety software, Affytrac, with multi-corrective action functionality. Users can now create an infinite amount of corrective actions for a single parent issue.

13 Jul 2010

GVK BIO receives AAALAC certification for animal facilities

GVK Biosciences Private Limited , Asia's leading Contract Research Organization, today announced that it received full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) International for its animal facilities.

12 Jul 2010

Data shows potential health benefits of S-equol in relieving menopausal symptoms

The findings of a scientific conference examining the growing body of research and potential health benefits of S-equol were published this month in the Journal of Nutrition. Manuscripts based on presentations made at the conference, which was organized by the Life Sciences Research Office, reveal data that S-equol is a safe, natural and effective solution to providing relief of menopausal symptoms such as hot flashes and muscle discomfort.

9 Jul 2010

Advanced Life Sciences announces positive results from preclinical studies of Restanza IV

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced positive results from preclinical toxicology and pharmacokinetic studies of an intravenous (IV) formulation of its novel antibiotic, Restanza™ that support its use in a hospital setting.

8 Jul 2010

Study finds additional targets for new therapies to treat advanced prostate cancer patients

In its early stages, prostate cancer requires androgens (hormones that promote the development and maintenance of male sex characteristics) for growth, and current first-line therapies target the receptor for these hormones to slow cancer's development and spread.

7 Jul 2010

Metabolon unveils novel approach to identify patients at preterm delivery risk

Metabolon, Inc., the leader in global metabolism, biomarker discovery and analysis, announces the publication of "Metabolomics in premature labor: a novel approach to identify patients at risk for preterm delivery", in The Journal of Maternal-Fetal and Neonatal Medicine.

3 Jul 2010

Advanced Cancer Therapeutics secures $10M in investments

Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that it has secured $10 million in investments from high net-worth individuals and institutions. This round of investment, which closed six months ahead of the company's year-end goal, will provide ACT additional capital to continue its development and commercialization of potentially lifesaving therapeutics for cancer patients.

2 Jul 2010

Chelsea initiates NORTHERA Phase III trial for symptomatic NOH associated with PD

Chelsea Therapeutics International, Ltd. announced the initiation of Study 306, a pivotal Phase III trial evaluating the efficacy of NORTHERA™, an oral synthetic precursor of norepinephrine, for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) associated with Parkinson's disease.

29 Jun 2010

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

New data were presented at the American Diabetes Association 70th Annual Scientific Sessions from a study comparing JANUMET (sitagliptin/metformin) to pioglitazone. In this study, JANUMET resulted in significantly greater blood sugar reductions in patients with type 2 diabetes compared with pioglitazone.

28 Jun 2010

Florida seeks new tools to stop dengue outbreak

While all eyes are on the Gulf oil spill, another natural disaster worsens as Key West Florida battles the first U.S. outbreak of dengue in 75 years. With over 30 confirmed cases (27 in 2009, 8 in 2010) and 5% of residents showing exposure to the mosquito-spread disease, Florida is seeking new tools to stop the emerging threat. Aiming to enhance their existing control program, the Florida Keys Mosquito Control District turned to SpringStar Inc in Woodinville, WA.

28 Jun 2010

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Merck announced that the Committee for Medicinal Products for Human Use adopted a positive opinion on the pending Marketing Authorization Application for SYCREST (asenapine) sublingual tablets. The CHMP has recommended that the European Commission grant a marketing authorization for SYCREST for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. The CHMP did not support an indication for the treatment of schizophrenia.

25 Jun 2010

Scientists report potential toxicity of nanoparticles in consumer products

Scientists are reporting that particle size affects the toxicity of zinc oxide, a material widely used in sunscreens. Particles smaller than 100 nanometers are slightly more toxic to colon cells than conventional zinc oxide. Solid zinc oxide was more toxic than equivalent amounts of soluble zinc, and direct particle to cell contact was required to cause cell death.

25 Jun 2010

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).

24 Jun 2010

Entelos agree to the terms of non-exclusive perpetual license to Metabolism Physiolab platform for Pfizer

Entelos, Inc. announced today that it has agreed to the terms of a non-exclusive perpetual license to its Metabolism Physiolab platform for Pfizer Inc. The perpetual license will include access for Pfizer to Entelos' PhysioLab Modeler software and its PhysioLab Simulation Server.

24 Jun 2010

Ricerca's Lyon facility obtains ISO 9001:2008 certification

Ricerca Biosciences, a uniquely integrated preclinical contract research drug development company providing services to the pharmaceutical industry, is pleased to announce that its Ricerca France, Lyon facility, has recently obtained the ISO 9001:2008 certification for all activities performed at the site.

22 Jun 2010

Toxicology News and Research

Latest Toxicology News and Research

JANA Partners sends detailed critique of Charles River's revised investor presentation on WuXi acquisition

Long-term exposure of arsenic may increase risk for lung cancer

Variations in quality of illegal Class B drug mephedrone could risk safety of users

Maven Semantic announces updates to database of Toxicology researchers

Research provides understanding of EGME's effects on metabolism

Affygility Solutions releases new version of Affytrac EH&S software with multi-corrective action functionality

GVK BIO receives AAALAC certification for animal facilities

Data shows potential health benefits of S-equol in relieving menopausal symptoms

Advanced Life Sciences announces positive results from preclinical studies of Restanza IV

Study finds additional targets for new therapies to treat advanced prostate cancer patients

Metabolon unveils novel approach to identify patients at preterm delivery risk

Advanced Cancer Therapeutics secures $10M in investments

Chelsea initiates NORTHERA Phase III trial for symptomatic NOH associated with PD

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

Florida seeks new tools to stop dengue outbreak

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Scientists report potential toxicity of nanoparticles in consumer products

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Entelos agree to the terms of non-exclusive perpetual license to Metabolism Physiolab platform for Pfizer

Ricerca's Lyon facility obtains ISO 9001:2008 certification

Forensics And Toxicology eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Toxicology News and Research

Latest Toxicology News and Research

Forensics And Toxicology eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in